European Innovation Council

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.

AMT Medical BV has developed a minimal invasive medical device for heart bypass surgery. The AMT Heart Bypass System is based on the ELANA bypass, technology invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team of the UMCU. The technique is designed to make the traditional heart bypass procedures faster, safer, easier and less invasive for the patient.The product has been fully developed, production process has been designed, all pre-clinical trials have finished, a clinical multi-center trial will commence late 2019, early 2020.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of an anatomically shaped polymer-based meniscus implant known as the Trammpolin. This innovative implant is designed to restore the protective function of the meniscus by acting as a spacer in the joint. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise gained from a collaborative initiative that began in 2010, which included universities, private companies, and support from the Dutch government. The company combines clinical, biomechanical, and polymer knowledge to advance the Trammpolin design and its prototype development.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, focused on developing genetically modified oncolytic viruses to improve cancer treatments. Established in 2013, the company aims to enhance tumor T-cell therapies through its patented technology, which utilizes oncolytic viruses to modify the tumor microenvironment and counteract its immune-suppressive properties. TILT Biotherapeutics is advancing several product candidates, including TILT-123, TILT-234, and TILT-321, and plans to translate its innovative approach into clinical trials. The technology is designed to bolster the effectiveness of tumor-infiltrating lymphocyte (TIL) therapies, chimeric antigen receptor (CAR-T) therapies, and checkpoint inhibitors, potentially achieving outcomes in solid tumors similar to those seen in hematological cancers.

TM Systems is an engineering and manufacturing company specializing in industrial air systems and solutions for process industries.

TM Systems is an engineering and manufacturing company specializing in industrial air systems and solutions for process industries.

MeMed Diagnostics Ltd. is a personalized diagnostics company established in 2009 and based in Tirat Carmel, Israel. The firm specializes in developing diagnostic solutions that focus on distinguishing between bacterial and viral infections to enhance patient care and reduce healthcare costs. Its flagship product, MeMed BV, is a test that analyzes patients' immune responses to differentiate between infection types. Additionally, the ImmunoDx platform combines proprietary biomarkers and algorithms to provide rapid and actionable insights for healthcare professionals, thereby addressing the challenge of antibiotic misuse, which is prevalent in healthcare systems worldwide. By accurately identifying the source of infection, MeMed's diagnostics aim to prevent inappropriate antibiotic prescriptions, mitigate the emergence of resistant bacterial strains, and ultimately improve treatment outcomes for infectious diseases.

Tessares is a Belgian company founded in 2015, specializing in software solutions aimed at enhancing the performance and quality of internet access. It focuses on developing and deploying Multipath TCP (MPTCP) technology, which allows network operators to combine various access technologies to improve internet speed for their customers. The company's flagship product, the Hybrid Access Solution, enables the efficient bonding of different network connections without the need for extensive infrastructure investments. Founded by key developers of the MPTCP protocol, Tessares aims to optimize internet delivery across wide geographic areas, ensuring a better overall experience for users. The company is privately owned and has secured initial funding from notable investors, including Proximus and VIVES.

Medicortex Finland is focused on developing a non-invasive, point-of-care diagnostic test for Traumatic Brain Injury (TBI) and concussions. Traditional diagnostic methods, such as CT and MRI scans, struggle to accurately diagnose mild TBIs. To address this, Medicortex is identifying brain injury biomarkers that can be detected from urine and saliva, with plans to incorporate these biomarkers into a hand-held diagnostic kit that provides rapid and reliable results without the need for medical professionals' interpretation. The company aims to collaborate with larger diagnostic firms for manufacturing and distribution. Its target customers include hospitals, emergency rooms, paramedics, military personnel, sports teams, pharmaceutical companies, and insurance providers. Medicortex has achieved significant milestones, including reaching Phase II clinical studies for its biomarker and receiving grant funding from the US Department of Defense, the European Union, and the Finnish Government.